Today the US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.
All News
Article
Article
Today the ACR began with the Great Debate, an intriguing set of Plenary presentations, a never-ending poster hall and a plethora of stimulation oral presentation sessions. Here are a few of my favorites from today:
David Liew
Tweet
What does CAR-T safety look like between autoimmune disease and heme-onc? Here's CRS and ICANS within the cohorts so far (although don't forget about the lymphodepletion) Anca Askanase @HSpecialSurgery #ACR26 @RheumNow https://t.co/GkDGDiOET4
IgG4-RD in 3 Talks: Shorter Steroids, Earlier B-Cell Therapy
IgG4-related disease now has two phase 3 trials and its first dedicated treatment guidelines. Glucocorticoids remain the weak point.
https://t.co/pWu1eoiMVG https://t.co/yXXk0R4Rbs
anita
Tweet
@RheumNow My top 5 from #ACR2026. #5. Abstract 2484. Addressing unmet needs in cSLE using #CARRA registry data. cSLE patients have significant burden of unmet therapeutic needs with currently approved therapies. Urgent call to expedite regulatory approvals of cSLE therapies!
Janet Pope
Tweet
#FcRn
#efigartigimod
+ #RCT in #IMNM & #DM
#LB24
But
๐ #SjD RCT stopped ๐ for
#futility
We will have niche Rx for many rare #SARDs I think over next few yrs
#ACR26 @ACRheum @RheumNow
David Liew
Tweet
Efgartigimod comes in with the first successful ph3 for IMNM (ALKIVIA trial)
Nipocalimab ph2 missed primary but big numerical diff
FcRN prob an obvious target for IMNM
In a debilitating disease with minimal other options, it's a very good time
ABSTLB24 ABST0905 #ACR26 @RheumNow https://t.co/c6RapsKKla
CD19 CAR-T relapse: 8/55 (14.5%), median 16.5 mo SLE 6.5%, SSc 20% (Scl70+), IIM 37.5% (ASyS) Relapsers: B-cell aplasia 77 vs 148 d, autoAb โ26% vs โ100% at M12 BCMA rescue: 7/7 major responses A flat autoAb curve is the warning sign. Abstr#2632 @RheumNow #ACR26 https://t.co/VFUiUN0FMG
Brian Jaros, MD
Tweet
What can we learn from large IgG4 dataset?
Epic Cosmos reviewed for IgG4 ICD codes
Total: 6.4k IgG4-RD & 128k matched controls
IgG4 patients:
- more HTN, HLD, DMII
- more MI, CVA, VTE
- more infections
- higher incident malignancy
@RheumNow #ACR26 #ABST2108 https://t.co/7mUOItGONP
Bella Mehta
Tweet
Among 5,598 kidney transplant recipients, graft failure was more frequent when ESKD was attributed to SLE than to other immune-mediated diseases, despite lower mortality. Transplant access and graft longevity are two different lupus outcomes. @rheumnow #ACR26 Abstract #1865 https://t.co/Ap76TQfGRI
Worse outcomes among young pts who develop anti-HMGCR myopathy
Hopkins cohort of 218 pts, statin naive pts more often younger (38.2 vs 59.8 years statin exposed)
In multivariable analysis, younger age independently predicted worse long term outcomes
This makes sense to me from
Audrey Gibson
Tweet
What if we could identify SLE BEFORE clinical disease develops?
New longitudinal proteomic research reveals distinct molecular trajectories preceding SLE progression. Could a future blood test help distinguish pts at risk from those who may never develop lupus? #1821 @RheumNow
Cancer in IgG4-RD: watch the first 3 yrs after dx
70% of post-dx cancers appear within 36 mo (n=13)
Types mirror the general population: prostate 25%, lymphoma 15%, colorectal 13%
Screen early and biopsy atypical lesions.
Emanuel Della Torre
@RheumNow #ACR26 https://t.co/DnCxqCR4cT
IgG4-RD has a season: onset clusters in winter
Peak in Jan, low in Jul-Aug
Pancreato-biliary drives the Jan peak
Season of onset: ฯยฒ=21.3, p<0.001
Points to an environmental trigger. Ask about the winter before onset.
Corona, ARD 2026 / Emanuel Della Torre
@RheumNow #ACR26 https://t.co/SSVyHoCj9b
David Liew
Tweet
Another one to watch today: ustekinumab in GCA
idea made popular @RichardPAConway https://t.co/SCJ5EyWpD2
this is a ph2 RCT IIS (now off patent)
benefit slow to emerge but present
why does this look okay, but guselkumab does not?
will a ph3 IIS happen?
ABST1896 #ACR26 @RheumNow https://t.co/7wZ4W4FSHH
Selective CAR-T for the win?
Chimeric autoantigen T cell receptor (CATCR)-T cells targeting PR3 were able to selectively deplete PR3-producing B cells, leaving the other ones alone
Possibly all the benefit with none of the harms? Currently #inmice
If the future is awesome, https://t.co/eUj9WQkUNR
Richard Conway
Tweet
Gliech at al. CAR-T 2.0 in AAV. PR3-CATCR-T cells selectively eliminate pathogenic PR3-ANCA+ B cells in AAV while sparing normal B cells and therefore avoiding off-target toxicity. Very prelimary but exciting! @RheumNow #ACR26 Abstr#0928 https://t.co/kibFxYL8Vy
Mortality in IIM-ILD: frontloaded but survival + improvement possible!
2 year mortality outcomes in a newly diagnosed IIM-cohort (n=41), 15% died @ median time of 8.5 months.
Of survivors, only 13.3% progressed, 46.7% improved as measured by % pred FVC. #ACR26 @Rheumnow
Richard Conway
Tweet
Terrier et al. RCT Mepolizumab vs conventional therapy for induction in EGPA. No sig diff day 168 remission (61% vs 51%). Did significantly increase sustained remission, glucocorticoid-free remission and EGPA-related event-free survival at day 364 @RheumNow #ACR26 Abst#0926
